Technology
Health
Pharmaceutical

Menlo Therapeutics

$7.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-0.26%) Today
-$0.02 (-0.26%) Today

Why Robinhood?

You can buy or sell MNLO and other stocks, options, ETFs, and crypto commission-free!

About

Menlo Therapeutics Inc. operates as biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded in October, 2011 and is headquartered in Redwood City, CA.

Employees
43
Headquarters
Redwood City, California
Founded
2011
Market Cap
179.36M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
167.16K
High Today
$7.84
Low Today
$7.60
Open Price
$7.77
Volume
17.99K
52 Week High
$38.82
52 Week Low
$3.74

Collections

Technology
Health
Pharmaceutical
Therapy
Biopharmaceutical
2018 IPO
US
North America

News

Markets InsiderMar 20

Menlo Therapeutics Announces New Board Member Elisabeth Sandoval

REDWOOD CITY, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Elisabeth Sandoval has been appointed as a member of Menlo’s Board of Directors, effective immediately. Ms. Sandoval currently serves as Chief Commercial Officer and Executive Vice President of Corporate Strategy for Alder Biopharmaceuticals, previously served as Chief Comme...

64
MarketBeatMar 7

Stock Price, News, & Analysis for Menlo Therapeutics

Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It is also developing products that are in Phase II clinical trials to treat pruritus associated with psoriasis, atopic dermatitis, and refractory chronic cough. The company was formerly known ...

23
Associated PressFeb 27

Menlo Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

REDWOOD CITY, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the fourth quarter and year ended December 31, 2018 and provided an update on its clinical development programs. “We are making solid progress in the clinical development of serlopitant for pruritus associated with prurigo nodularis (PN), our most advanced i...

481

Earnings

-$0.89
-$0.78
-$0.67
-$0.56
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.